Menu

Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension

September 28, 2026

Mumbai, India, Naples, FL, September 28, 2026: Global pharma major, Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL via the 505(b)(2) pathway.

Lupin's Apixaban Oral Suspension 1.25 mg/mL is an oral liquid formulation of apixaban, the active ingredient in Eliquis® (apixaban) of Bristol Myers Squibb, and provides an alternative administration option for adult patients requiring anticoagulation therapy Including those who may have difficulty swallowing tablets.

“This tentative approval reflects our continued focus on developing differentiated medicines that address meaningful patient needs. Apixaban oral suspension expands the ways in which this important therapy could be administered, while reinforcing our commitment to building a differentiated portfolio,” said Vinita Gupta, CEO, Lupin.

Upon final approval, the product will be manufactured at Lupin's Somerset, New Jersey facility, leveraging the company's U.S.-based manufacturing expertise to support high-quality standards, and supply reliability.

About Lupin 
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with a strong presence across India, the U.S., Other Developed Markets, and Emerging Markets, with products distributed in over 100 markets. Lupin has a diversified portfolio spanning generics, complex generics, specialty medicines, and biosimilars, and continues to strengthen its market position through a differentiated portfolio. The company maintains strong leadership in the U.S. and India across core therapeutic areas, including cardiovascular, respiratory, diabetes, gastrointestinal, and women’s health. 15 state-of-the-art manufacturing facilities support sustainable operations, with 6 research centers and a dedicated workforce of over 26,000 professionals. Lupin continues to expand the healthcare ecosystem through diagnostics, digital health, patient-support programs, and disease management initiatives. Sustainability continues to be a core pillar of the company’s business strategy.

To know more, visit www.lupin.com or follow us on LinkedIn 
https://www.linkedin.com/company/lupin

For further information or queries please contact:

Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com

Elise Titan
Director – U.S. Communications, Lupin
elisetitan@lupin.com

*Safe Harbor Statement
Eliquis is a registered trademark of Bristol-Myers Squibb Company

Latest Press Releases

Smart Guide
Consent to Collection Cookie

This website uses cookies to enhance your overall web browsing experience, provide you with ads tailored to your interests, and allow us to measure our audience and collect other analytical data about the use of our website.

By clicking "Accept All" you consent to the collection of your personal information (which may include your Consumer Health Data) through 1st and 3rd party cookies (or similar). To edit your cookie preferences, use the options below.

For more information, please visit our Privacy Statement.

Depending on where you live, you may also be able to exercise your right to opt out or withdraw your consent.Do Not Sell/Share My Personal Information.

Global Privacy Control Detected

We have detected your Global Privacy Control (GPC) signal. In accordance with applicable privacy laws, we have automatically honored your preference and disabled all non-essential cookies and tracking.

Only necessary cookies required for the website to function are enabled.

Opt-Out Request Honored

We have respected your privacy preference. Your opt-out request through cookie settings or Global Privacy Control signal has been honored.